Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

less invasive treatment option. The Medtronic PulseSelect™ Pulsed Field Ablation System uses pulsed electric fields to target and eliminate the muscle cells that cause AFib. This innovative ...

Saint Francis treated its first patient with pulsed-field ablation, which delivers pulsed electric fields to tissue to treat ...

Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it. Whenever he’d overexert himself, he’d feel “different,” but it would go away with rest.

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...